Browse studies

Find your next paid study

135 recruiting studies matching your filters

Phase II Open Label Prospective Nonrandomized Trial of Belumosudil for Switch-Maintenance Prophylaxis of Graft-versus-Host Disease in Allogeneic Hematopoietic Cell Transplantation

The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an eff…

Graft Versus Host DiseaseGraft Vs Host DiseaseHematologic Malignancy

Estimated

~$75 – $2,000

Actual pay is set by the research site.

Memorial Sloan Kettering Cancer CenterNCT07006506

Phase 2

Efficacy and Safety of PUL-042 Inhalation Solution in Reducing Lower Respiratory Tract Complications in Patients With Hematologic Malignancies and Recipients of Hematopoietic Stem Cell Transplantation (HSCT) With Documented Viral Infections With PIV, hMPV or RSV

The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity …

Hematologic MalignanciesHematopoietic Stem Cell Transplant (HSCT)

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Pulmotect, Inc.NCT06665100

Phase 2

Prospective Evaluation of Xerava™ (Eravacycline) Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoie…

Hematological MalignancyNeutropenia

Estimated

~$75 – $2,000

Actual pay is set by the research site.

West Virginia UniversityNCT05537896

Tumor Cell and DNA Detection in the Peripheral Blood of Patients With Hematological Malignancy

Acute myeloid leukemia (AML) accounts for more than 40% of leukemia mortality in the United States. Each year around ten thousand people die from the disease, …

Hematological Malignancy

Estimated

~$10 – $750

Actual pay is set by the research site.

University of Missouri-ColumbiaNCT04841447

Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-…

Relapsed Pediatric ALLHematopoietic Cell TransplantationHematologic Malignancy

Estimated

~$150 – $3,000

Actual pay is set by the research site.

St. Jude Children's Research HospitalNCT07257419

Phase 3

A Phase 3b Study to Evaluate Efficacy and Safety of a Single Dose of Autologous CRISPR Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (CTX001) in Subjects With Transfusion-Dependent β-Thalassemia or Severe Sickle Cell Disease

This is a single-dose, open-label study in participants with transfusion-dependent β-thalassemia (TDT) or severe sickle cell disease (SCD). The study will eval…

Beta-ThalassemiaThalassemiaHematologic Diseases+4 more

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Vertex Pharmaceuticals IncorporatedNCT05477563

Phase 1

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

Background: High-risk blood cancers (leukemias and lymphomas) often come back after treatment, and many cannot be cured with chemotherapy alone. These cancers…

Hematologic MalignanciesHematologic Neoplasms

Estimated

~$150 – $2,700

Actual pay is set by the research site.

National Cancer Institute (NCI)NCT07162038

Observational

A Single-center Pilot Study Using TCRα/β and CD45RA Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Cell Transplantation in Adults(HAPLO2022)

This is a single-center, open-label, single-arm, pilot clinical study using TCRα/β and CD45RA depleted stem cell grafts from haploidentical donors for hematopo…

Hematological Malignancies

Estimated

~$10 – $1,050

Actual pay is set by the research site.

Miltenyi Biomedicine GmbHNCT06225050

InAdvance: Surveillance, Prevention, and Interception in a Population at Risk For Cancer

This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or…

Cancer RiskCancer Predisposition SyndromeHereditary Cancer Prediction+28 more

Estimated

~$10 – $1,125

Actual pay is set by the research site.

Phase 1

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute m…

AMLAML With Mutated NPM1Hematologic Malignancy+9 more

Estimated

~$150 – $4,200

Actual pay is set by the research site.

Kura Oncology, Inc.NCT06001788

The Rutgers University Study of the Genetics of Blood Cancers

The goal of this study is to enroll at least 10,000 participants nationally including affecteds and unaffecteds via online study portal, collect surveys online…

Blood CancersBlood CancerLeukemia+6 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Rutgers, The State University of New JerseyNCT07714044

Phase 1

IIT2022-03-Paquette-GeriBMT: A Phase I Study of De-Escalation of Post-Transplant Cyclophosphamide Dosing in Patients Aged >/= 65 Years Undergoing Conditioning With Fludarabine and Total Body Irradiation 800 cGy

The purpose of this phase 1 study is to determine the optimal dose of the immune suppressive drug, cyclophosphamide, following standard allogeneic stem cell tr…

Hematologic Malignancies

Estimated

~$150 – $4,500

Actual pay is set by the research site.

Ronald PaquetteNCT05849207